Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s board of directors ...

Veru Inc (VERU) reports positive Phase 2B study ... significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average lost 71% less ...

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants who took Zepbound lost more weight than those who took Wegovy.

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

Veru Inc. updates on its Phase 2b clinical trials ... patients receiving semaglutide (Wegovy Enobosarm + semaglutide treatment resulted in dose dependent greater loss of fat mass compared to ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers ...

Newer medications, such as Mounjaro and Wegovy, exhibit both more total weight lost and faster weight regain than older medications Montinique Monroe/Bloomberg via Getty A new analysis determined ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

The GLP-1 RA may be either WEGOVY (semaglutide ... to be Available for Phase 3 Clinical Studies and Commercialization Veru is currently developing a novel, patentable, modified release oral ...

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...